Published in
Translational Lung Cancer Research, 7(10), p. 3093-3105, 2021
DOI: 10.21037/tlcr-21-197
Links
Tools
Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV
Journal article published in 2021 by
Wolfgang M. Brueckl,
Martin Reck,
Achim Rittmeyer,
Jens Kollmeier,
Claas Wesseler 
,
Gunther H. Wiest,
Petros Christopoulos ,
Albrecht Stenzinger,
Amanda Tufman,
Petra Hoffknecht,
Bernhard Ulm,
Fabian Reich,
Joachim H. Ficker,
Eckart Laack
,
Gunther H. Wiest,
Petros Christopoulos ,
Albrecht Stenzinger,
Amanda Tufman,
Petra Hoffknecht,
Bernhard Ulm,
Fabian Reich,
Joachim H. Ficker,
Eckart Laack
